Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Jiyoung Ahn, Yu Sung Choi, Eric L. Simpson
Annals of Dermatology (2021) Vol. 33, Iss. 1, pp. 1-1
Open Access | Times Cited: 18

Showing 18 citing articles:

Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets
Luca Fania, Gaia Moretta, Flaminia Antonelli, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2684-2684
Open Access | Times Cited: 70
Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis
Hye Sung Han, Young Gue Koh, Jun Ki Hong, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 13
Discovery of biomarkers in the psoriasis through machine learning and dynamic immune infiltration in three types of skin lesions
Xiao Zhou, Han Zhou, Xin Luo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Biologic and Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Mechanistic Considerations
Camille Rothenberg‐Lausell, Jonathan Bar, Dante Dahabreh, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 20-30
Closed Access | Times Cited: 4
First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, et al.
Clinical Pharmacology in Drug Development (2025)
Open Access
A new era of atopic eczema research: Advances and highlights
Claudia Hülpüsch, Andreas Benedikt Weins, Claudia Traidl‐Hoffmann, et al.
Allergy (2021) Vol. 76, Iss. 11, pp. 3408-3421
Open Access | Times Cited: 27
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Marina Calabrese, Martina D’Onghia, Laura Lazzeri, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 775-775
Open Access | Times Cited: 3
A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
Dong Hyek Jang, Seok‐Jae Heo, Hyung Don Kook, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 22
The changes of leukocytes and T lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in control group in pollen season compared to out of pollen season
Jarmila Čelakovská, Eva Čermáková, Petra Boudková, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Autologous Th2‐polarized lymphocytes induce atopic dermatitis lesions in non‐atopic human skin xenotransplants
Aviad Keren, Kristian Reich, Marta Bertolini, et al.
Allergy (2023) Vol. 78, Iss. 6, pp. 1538-1553
Open Access | Times Cited: 5
The differences in the count of B lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in healthy subjects in pollen season and out of pollen season
Jarmila Čelakovská, Eva Čermáková, Ctirad Andrýs, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Dupilumab treatment in paediatric atopic dermatitis (2 to 18 years): Spanish multicentre retrospective real-life study
Helena Iznardo, Esther Roé, Asunción Vicente, et al.
Clinical and Experimental Dermatology (2024)
Closed Access | Times Cited: 1
Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
Dong Hun Lee, Hyun‐Chang Ko, Chan Ho Na, et al.
Annals of Dermatology (2022) Vol. 34, Iss. 2, pp. 157-157
Open Access | Times Cited: 6
Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis
Kelsey B. Nusbaum, Sarah Fleischer, Alan B. Fleischer
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 5, pp. 2534-2544
Closed Access | Times Cited: 6
Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis
Sul Hee Lee, Youin Bae, Young Lip Park
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6255-6255
Open Access | Times Cited: 3
Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy
Jarmila Čelakovská, Eva Čermáková, Petra Boudková, et al.
Immunological Medicine (2024), pp. 1-14
Open Access
Dermatologist's Perspective on the Medical Environments for Skin Disorders
Seong Jin Jo
Health Insurance Review & Assessment Service Research (2021) Vol. 1, Iss. 1, pp. 113-118
Open Access | Times Cited: 1
Pruritus
Magda Blessmann Weber, Fernanda Oliveira Camozzato, Júlia Kanaan Recuero
Springer eBooks (2023), pp. 1607-1636
Closed Access
Biologics in the Management of Sever Atopic Dermatitis
Mohammed Al Abadie, Zinah Sharara, S. Abadie, et al.
International Journal of Clinical & Experimental Dermatology (2023) Vol. 8, Iss. 2, pp. 49-55
Open Access
Page 1

Scroll to top